PTX Stock Overview
A clinical stage oncology company, develops drugs for the treatment of various cancers in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Prescient Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.038 |
| 52 Week High | AU$0.10 |
| 52 Week Low | AU$0.037 |
| Beta | 1.16 |
| 11 Month Change | -19.15% |
| 3 Month Change | -19.15% |
| 1 Year Change | -45.71% |
| 33 Year Change | -82.73% |
| 5 Year Change | -56.82% |
| Change since IPO | -49.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| PTX | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -5.0% | -3.8% | 0.9% |
| 1Y | -45.7% | 9.9% | 17.7% |
Return vs Industry: PTX underperformed the Australian Biotechs industry which returned 10% over the past year.
Return vs Market: PTX underperformed the Australian Market which returned 17.2% over the past year.
Price Volatility
| PTX volatility | |
|---|---|
| PTX Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 17.2% |
| 10% least volatile stocks in AU Market | 3.3% |
Stable Share Price: PTX has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: PTX's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | n/a | Steven Yatomi-Clarke | ptxtherapeutics.com |
Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-100, a first in class compound with the ability to block an cancer growth enzyme, thereby disrupting the oncogenic Ras pathway. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014.
Prescient Therapeutics Limited Fundamentals Summary
| PTX fundamental statistics | |
|---|---|
| Market cap | AU$30.60m |
| Earnings (TTM) | -AU$8.24m |
| Revenue (TTM) | AU$3.71m |
8.2x
P/S Ratio-3.7x
P/E RatioIs PTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PTX income statement (TTM) | |
|---|---|
| Revenue | AU$3.71m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$3.71m |
| Other Expenses | AU$11.95m |
| Earnings | -AU$8.24m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.01 |
| Gross Margin | 100.00% |
| Net Profit Margin | -221.91% |
| Debt/Equity Ratio | 1.8% |
How did PTX perform over the long term?
See historical performance and comparison